This study arose from a desire to improve the mitotic yields from leukaemic marrows submitted for cytogenetic analysis. We therefore decided to investigate the effect of culture conditions and the addition of stimulating factors to bone marrow suspension cultures set up for chromosomal analysis. The stimulating factors were prepared in the same way as colony stimulating factor (CSF) used to promote growth of granulocytic bone marrow cells in soft agar (Chervenick and Boggs, 1970) .
Material and methods

BONE MARROW SAMPLES
The bone marrow samples were obtained from patients at the Royal Marsden Hospital, Surrey, who required cytological assessment of their bone marrow.
For the purposes of this paper normal marrows were defined as those from non-leukaemic patients. In the majority of cases these patients were haematologically normal, but two showed marrow infiltration, one with melanoma and one with lymphoma. However, the chromosomes of the cells in division appeared normal. Another patient had a leukaemoid reaction, and a fourth aspirate showed abnormal cytological features of the erythroid series but granulopoiesis was normal. The remaining 43 samples classified as normal showed normal haemaReceived for publication 6 November 1975 topoiesis. The study also included bone marrow samples from 26 patients with untreated acute myeloid leukaemia (AML).
A bone marrow sample from a patient with red cell aplasia and blood samples showing high leucocyte counts from two patients with Philadelphia (Ph) chromosone positive chronic myeloid leukaemia (CML) were also investigated but are not included in the tables.
PREPARATION OF BONE MARROW STIMULATING FACTORS
The stimulating factor was prepared according to the method of Chervenick and Boggs (1970) for production of CSF. The leucocytes, 1-5 x 109 cell/l, were incubated for 10 days in McCoy's SA at 37°C in 5% C02 in air as it is essential to maintain an acid pH. After incubation the cells were spun down at 200 g and the supernatant bone marrow stimulating factor (BMSF) was removed and stored at -200C until used. Batches of factor (BMSF-N) were produced from 15 normal individuals and from three patients with AML, CML, and chronic myelomonocytic leukaemia (BMSF-L). PREPARATION Preliminary experiments were done in order to determine whether the composition of the medium or time in culture affected the mitotic yields in bone marrow cultures. In the standard so-called 'direct' preparation for cytogenetic analysis the bone marrow is incubated for 2 hours at 37°C in buffered salt solution (Tjio and Whang, 1962 The preparations of BMSF-L appeared to be active and the same patterns of response followed as with Factors influencing mitotic yieldsfrom suspension cultures ofnormal and acute leukaemic bone marrows 585 BMSF-N when they were applied to both normal and leukaemic bone marrow samples. When a stimulatory result was obtained with BMSF-N the increase in mitotic activity obtained with BMSF-L was usually less.
EVIDENCE THAT BMSF-N STIMULATES MYELOID CELLS
BMSF-N does not stimulate mitoses in normal peripheral blood lymphocyte cultures.
In blood cultures from two Ph' positive patients the mitoses obtained with and without BMSF-N were Ph' positive. No Ph' negative mitoses were seen in the cultures with BMSF-N. In blood from these patients, cultured with phytohaemagglutinin, both Ph' positive and negative cells were observed.
One of the patients with AML had an abnormal chromosome, 16q+, in some of the bone marrow metaphases. This 16q+ chromosome was also seen in divisions obtained after the addition of BMSF-N. The patient never went into remission and the 16q + was still present in the bone marrow sample incubated with and without BMSF-N after treatment.
Additional supportive data come from a case of red cell aplasia. The yield of mitoses at 2 hours and at 24 hours in cultures without BMSF-N was 117 and 347 respectively, indicating a normal marrow response pattern. After addition of BMSF-N the number of mitoses was increased, the ratio (number of mitoses + BMSF-N/number of mitoses in control) being 3 9 at 2 hours and 1-7 at 24 hours.
Discussion
Cytogenetic analyses of bone marrow cells are often restricted by an inadequate yield of dividing cells even in samples of adequate cellularity. This is surprising in view of the fact that the marrow is in cycle, up to 34 % of the cell population being capable of dividing, with a generation time of between one and two days (Wintrobe et al, 1974) Even though the generation time of myeloid cells in AML may be longer than normal, this is compensated for by a very high proportion of cells having division potential (Clarkson et al, 1967; Clarkson et al, 1970) . Rather than proposing an inadequate mitotic rate in the marrow as the cause of cytogenetic failure, it is pertinent to consider whether the deficiency of mitoses is due to the non-physiological conditions used in processing the marrow. It is therefore relevant that we have observed an increased mitotic yield when using enriched media.
Even using the enriched medium the number of mitoses observed in normal bone marrows at 24 hours was greater than at 2 hours. This appears to be the typical normal response. On the other hand, marrows from untreated patients with AML usually yield fewer mitoses at 24 hours than at 2 hours.
Normal human bone marrow contains cells which proliferate and mature in semisolid media under the influence of CSF, producing clusters and colonies ranging in size from 3 to 300 cells. Some acute myeloid leukaemic marrow also contains such cells, although the frequency of the large colonies is less and the incidence of clusters often increased (Metcalf, 1973) .
CSF has been described as a glycoprotein with molecular weight of 45000 daltons. Others have suggested that CSF is composed of subunits of 15-20 000 daltons and that by combination the MW might vary from 15 000 to 70 000 daltons. CSF is species non-specific, produced by monocytes, and is thought to participate in the regulation of normal granulopoiesis in vivo as well as serving as a stimulating factor in semisolid media (Metcalf, 1973) . These factors may be produced in a variety of ways.
In our studies we used the technique of Chervenick and Boggs (1970) to produce BMSF, and we have found the supernatant from these cultures to be capable of stimulating mitoses in suspension cultures in both normal and leukaemic marrows. Since we have not proved our material to be identical with CSF, we have chosen to call it BMSF. Further studies may show that both factors are identical.
It is possible that the effects of BMSF-N are due to a speeding up of mitotic rate rather than recruitment of dormant cells into the mitotic pool. It appears that BMSF-N can cause either an increase or decrease in mitotic yield from normal marrows (tables II and III), and alteration of mitotic cycle time could explain both effects. The action of BMSF-N on AML marrows was also variable but more often stimulatory than inhibitory.
Some preliminary experiments on factors made from patients with chronic and acute myeloid leukaemia indicate that BMSF can be produced by the leucocytes of these patients. The success may simply mirror the state of the monocyte population. Goldman et al (1974) failed to make CSF from the cells of patients with Philadelphia positive CML chromosome and high leucocyte counts but succeeded when the counts were normal after treatment.
BMSF-N does not act as a mitotic stimulant of normal lymphocytes. By using abnormal chromosomes present in cells of myeloid origin as markers, we have been able to show that BMSF-N does stimulate cells of the myeloid series in suspension cultures. Whether the factor also stimulates the erythrocytic and megakaryocytic series remains to be seen.
Our study shows that mitotic yields in normal marrows may be increased by enriching the media and by using 24-hour incubation times. The addition of BMSF-N to 2-hour cultures in an enriched medium appears to be the best way of improving the prospects for cytogenetic analysis in AML. 
